← Eichor
Condition: Uterine Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Uterine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04997096Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04712851Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
Phase 2 · 1 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06640283Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
Phase N/A · 1 location(s) · National Cancer Institute, Naples · NCT06893861Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unr
Phase 1 · 1 location(s) · Aaron Wolfson · NCT05603910Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Phase 2 · 2 location(s) · Panagiotis Konstantinopoulos, MD, PhD · NCT06518564A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brach
NA · 1 location(s) · Ain Shams University · NCT07343531Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)
Phase N/A · 1 location(s) · Region Västerbotten · NCT05855941PErsonalized TReatment for Endometrial Carcinoma
NA · 1 location(s) · University of Helsinki · NCT05655260A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Phase 2 · 3 location(s) · Yale University · NCT02491099Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT07527143BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT07062016Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Phase 2 · 2 location(s) · Joyce Liu, MD · NCT06369155A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800612Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07336147Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT06239194Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdH
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06253494Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06529809Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Phase 1 · 1 location(s) · Lindsay Ferguson, MD · NCT06191133ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05542407Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.